CDKN2A and meningioma: Among these, CDKN2A/B (cyclin-dependent kinase inhibitor 2A and 2B) deletions, both heterozygous and homozygous, are strongly associated with shortened time to meningioma progression, with hazard ratios of 5.5 (heterozygous deletion) and 8.4 (homozygous deletion), with prevalence rising by WHO grade and reaching 28.9% homozygous loss in WHO grade 3 tumors (66).